Big pharma's view of biotech valuations, in real time.
M&A is the most direct signal of how big pharma values biotech. When deal volume rises and premiums expand, it means acquirers see today's biotech prices as cheap relative to long-run pipeline value — a leading indicator that often precedes biotech sentiment recovery.
Aggregate value, median premium, and days-since-megadeal require parsing 8-K body text. That parser is in development — fields appear here once values are extracted.
Why this matters for retail
Pharma giants face a wall of patent expirations through 2030 — roughly $200B in revenue at risk across the basket. Their pipelines do not internally produce enough new assets to fully replace that revenue. So they buy.
That structural pressure means M&A is not a luxury, it's a necessity. The question isn't whether they'll acquire — it's at what valuation. When premiums compress (acquirers paying small markups over market price), it means biotech is already priced expensively. When premiums expand, biotech is being valued cheaply by the people who should know best.
Watching premiums and deal velocity is, in effect, watching how the most informed valuation arbiters see the small-cap biotech market.
Recent definitive agreements
Drawn from SEC 8-K filings tagged for Item 1.01 (Entry into a Material Definitive Agreement). The acquirer is one of the 15 pharma giants we monitor. Click the accession to read the original SEC filing.
- Loading recent deals…
How to read these stats
- Deals 90d rising: consolidation phase, pipelines being filled. Bullish for biotech valuations.
- Median premium expanding: acquirers paying up. Strong signal that biotech is undervalued vs. pipeline value.
- Aggregate value spiking: can be one megadeal (less informative) or broad-based activity (more informative). Read alongside deal count.
- Days since megadeal climbing: dry spell. If pipelines are weakening too, often precedes sector rotation.
What's not here yet
The premium percentages, aggregate values, and days-since-megadeal numbers require parsing the 8-K body text — that work is in v1.4. The deal list (acquirer, target, date, accession) is fully wired. When the parser ships, the stats above will populate retroactively from the same filings already in our database.
For full pipeline-stage M&A research with target databases and clinical-stage filters, see BiopharmCatalyst (paid). Our M&A Pulse is sentiment-focused, not deal-research-focused.